James E Deerfield Mgmt L.P.... Net Worth

The estimated Net Worth of James E Deerfield Mgmt L.P.... is at least $4.03 Million dollars as of 4 December 2015. James P owns over 272,249 units of Alimera Sciences stock worth over $4,029,811 and over the last 9 years James sold ALIM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James P ALIM stock SEC Form 4 insiders trading

James has made over 11 trades of the Alimera Sciences stock since 2015, according to the Form 4 filled with the SEC. Most recently James bought 272,249 units of ALIM stock worth $819,469 on 4 December 2015.

The largest trade James's ever made was buying 390,040 units of Alimera Sciences stock on 19 October 2015 worth over $1,158,419. On average, James trades about 184,143 units every 5 days since 2015. As of 4 December 2015 James still owns at least 728,718 units of Alimera Sciences stock.

You can see the complete history of James P stock trades at the bottom of the page.

Insiders trading at Alimera Sciences

Over the last 15 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo, and Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.

What does Alimera Sciences do?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

Complete history of James P stock trades at Alimera Sciences

Alimera Sciences executives and stock owners

Alimera Sciences executives and other stock owners filed with the SEC include:

• Richard Eiswirth,
  President, Chief Executive Officer, Director
• C. Daniel Myers,
  Non-Executive Chairman of the Board
• Richard S. Eiswirth Jr.,
  Pres, CEO & Director
• David Holland,
  Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets
• Philip Ashman,
  Chief Operating Officer, Senior Vice President - Commercial Operations Europe
• David R. Holland,
  Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets
• Dr. Philip Ashman,
  COO & Sr. VP of Commercial Operations - Europe
• Charles Daniel Myers,
  Non-Exec. Chairman & Consultant
• James Largent,
  Lead Independent Director
• John Marco,
  Investor Relations
• Mary Szela,
  Independent Director
• John Snisarenko,
  Independent Director
• Peter Pizzo,
  Independent Director
• Garheng Kong,
  Independent Director
• Brian Halak,
  Independent Director
• Samer Kaba,
  Chief Medical Officer
• Phil Jones,
  Chief Financial Officer
• Dr. David Dyer,
  Chief Retina Specialist
• Christopher S. Visick,
  VP, Gen. Counsel & Sec.
• J. Philip Jones,
  Chief Financial Officer
• Calvin W. Roberts,
  Director
• Glen Bradley,
  Director
• James E Deerfield Mgmt L.P....,
  
• Mark J Brooks,
  Director
• Kenneth Green,
  SVP & Chief Scientific Officer
• L.P.Mitchell Kateo'driscoll...,
  
• Alto Investors Lp Palo,
  
• Russell Skibsted,
  Chief Financial Officer & SVP
• Capital, Llc Armistice Capi...,
  
• Patrick Lee,
  10% owner
• Management Viii, L.L.C.Sofi...,
  
• Partners Vi, L.P.Blair Jame...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Jesse I Treu,
  10% owner
• Venture Management Co Iv Ll...,
  
• Philip R Tracy,
  Director
• Susan Caballa,
  SEE REMARKS
• Kathleen K Schoemaker,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• James C Blair,
  10% owner
• Nicole Vitullo,
  10% owner
• Anders D Hove,
  Director
• Bryce Youngren,
  Director
• Brian H Dovey,
  10% owner
• Vi Associates, L.P. Dp,
  10% owner
• Associates Iv L P Venrock M...,
  
• Associates Vi, Llc Mumma Mi...,
  
• Associates Vii, Llc Mumma M...,
  
• Associates V, Llc Mumma Mit...,
  
• L.P.Bock Louis Cmitchell Ka...,
  
• Adam Morgan,
  Director
• Stanley Morgan,
  10% owner
• Todd Michael Wood,
  President of U.S. Operations
• Roger Sawhney,
  Director
• Adam Velan Capital Investme...,
  
• Partners Lpjohnson David Ed...,
  
• Jason M. Werner,
  Chief Operating Officer
• Erin Parsons,
  
• Michael Kaseta,
  
• Ross D De Mont,
  
• Margaret Pax,
  
• Elliot Maltz,
  Chief Financial Officer